Seminar Series
Title
Applications of Pharmacoepidemiology: Indirect Treatment Comparisons and Their Role in the Global Pharmaceutical Industry
Speaker
Dr. Chris Cameron
Time and Date
12 – 1 pm, Wednesday, May 14, 2025
Location
MS Teams Join the meeting now
(https://shorturl.at/WN2YB)
Bio
Dr. Chris Cameron is a life sciences executive, entrepreneur, and academic with extensive experience in health economics, indirect treatment comparisons, HTA, and real-world data analytics. He was a partner/owner at Cornerstone Research Group and helped it grow to become Canada's largest HEOR consultancy, until it was acquired by EVERSANA. He is the currently Chief Scientific Officer at EVERSANA, where he leads scientific strategy for many of the world’s largest pharmaceutical and medical device companies. Chris is also an adjunct professor in the Department of Community Health and Epidemiology at Dalhousie University and has authored over 175 peer-reviewed publications in top journals. His work in indirect treatment comparisons has been globally recognized. Chris holds an MSc and PhD in Epidemiology from Dalhousie University and University of Ottawa, and has completed a fellowship at Harvard University.
Synopsis
Pharmacoepidemiology plays a pivotal role in shaping evidence-based decision-making in the pharmaceutical industry, particularly through methodologies like indirect treatment comparisons (ITCs). These comparisons are essential for evaluating the efficacy and safety of treatments when head-to-head clinical trials are not feasible. In this seminar, Dr. Chris Cameron will explore the applications of ITCs in real-world settings, and how they contribute global pharmaceutical industry with a focus on global health technology assessments. The discussion will also highlight the integration of strategy, technology, AI & advanced analytics in enhancing the robustness and reliability of ITCs. Attendees will gain insights into the challenges and opportunities of implementing ITCs in a rapidly evolving industry landscape, as well as their broader use to support pharmaceutical reimbursement.